Format
Sort by
Items per page

Send to

Choose Destination

Best matches for MK4305 OR Suvorexant OR "mk-4305":

Suvorexant: scientifically interesting, utility uncertain. Keks NA et al. Australas Psychiatry. (2017)

Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Kuriyama A et al. Sleep Med Rev. (2017)

Profile of suvorexant in the management of insomnia. Sutton EL et al. Drug Des Devel Ther. (2015)

Search results

Items: 1 to 20 of 86

  • Filters activated: Toxicology. Clear all to show 198 items.
1.

Toward the Mysteries of Sleep.

Yanagisawa M.

Keio J Med. 2019;68(1):27. doi: 10.2302/kjm.68-001-ABST.

2.

Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK.

Clin Drug Investig. 2019 May;39(5):453-454. doi: 10.1007/s40261-019-00777-6.

PMID:
30895461
3.

Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK.

Clin Drug Investig. 2019 May;39(5):441-451. doi: 10.1007/s40261-019-00764-x. Erratum in: Clin Drug Investig. 2019 Mar 20;:.

PMID:
30810914
4.

Expanded table: Some oral hypnotics for chronic insomnia.

[No authors listed]

Med Lett Drugs Ther. 2018 May 7;60(1546):e209-e213. Review. No abstract available.

PMID:
30625124
5.

Drugs for chronic insomnia.

[No authors listed]

Med Lett Drugs Ther. 2018 Dec 17;60(1562):201-205. Review. No abstract available.

PMID:
30625122
6.

Suvorexant-Induced Delirium.

Yoshida K, Nakamura K, Yasui-Furukori N.

Prim Care Companion CNS Disord. 2018 Nov 15;20(6). pii: 18l02297. doi: 10.4088/PCC.18l02297. No abstract available.

7.

Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods.

Janockova J, Dolezal R, Nepovimova E, Kobrlova T, Benkova M, Kuca K, Konecny J, Mezeiova E, Melikova M, Hepnarova V, Ring A, Soukup O, Korabecny J.

Molecules. 2018 Nov 9;23(11). pii: E2926. doi: 10.3390/molecules23112926.

8.

Methyl-containing pharmaceuticals: Methylation in drug design.

Sun S, Fu J.

Bioorg Med Chem Lett. 2018 Nov 1;28(20):3283-3289. doi: 10.1016/j.bmcl.2018.09.016. Epub 2018 Sep 14. Review.

PMID:
30243589
9.

Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting.

Tamura K, Maruyama T, Sakurai S.

Ann Thorac Cardiovasc Surg. 2019 Feb 20;25(1):26-31. doi: 10.5761/atcs.oa.18-00038. Epub 2018 Aug 9.

10.

Quantification of suvorexant in blood using liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry.

Skillman B, Kerrigan S.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 1;1091:87-95. doi: 10.1016/j.jchromb.2018.05.006. Epub 2018 May 25.

PMID:
29859493
11.

Prescription Drugs Used in Insomnia.

Dujardin S, Pijpers A, Pevernagie D.

Sleep Med Clin. 2018 Jun;13(2):169-182. doi: 10.1016/j.jsmc.2018.03.001. Review.

PMID:
29759268
12.

Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men.

Yee KL, McCrea J, Panebianco D, Liu W, Lewis N, Cabalu T, Ramael S, Wrishko RE.

Clin Drug Investig. 2018 Jul;38(7):631-638. doi: 10.1007/s40261-018-0650-4.

PMID:
29705869
13.
14.

Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.

Atkin T, Comai S, Gobbi G.

Pharmacol Rev. 2018 Apr;70(2):197-245. doi: 10.1124/pr.117.014381. Review.

PMID:
29487083
15.

Computational studies on horseshoe shape pocket of human orexin receptor type 2 and boat conformation of suvorexant by molecular dynamics simulations.

Bai Q, Pérez-Sánchez H, Shi Z, Li L, Shi D, Liu H, Yao X.

Chem Biol Drug Des. 2018 Jul;92(1):1221-1231. doi: 10.1111/cbdd.13181. Epub 2018 Mar 8.

PMID:
29450984
16.

Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study.

Masuyama T, Sanui M, Yoshida N, Iizuka Y, Ogi K, Yagihashi S, Nagatomo K, Sasabuchi Y, Lefor AK.

Psychogeriatrics. 2018 May;18(3):209-215. doi: 10.1111/psyg.12314. Epub 2018 Feb 8.

PMID:
29423967
17.

CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes-Tasimelteon as an Example.

Preskorn SH.

J Psychiatr Pract. 2017 Nov;23(6):425-430. doi: 10.1097/PRA.0000000000000274.

PMID:
29303950
18.

Tissue Distribution of Suvorexant in Three Forensic Autopsy Cases.

Waters B, Hara K, Ikematsu N, Takayama M, Matsusue A, Kashiwagi M, Kubo SI.

J Anal Toxicol. 2018 May 1;42(4):276-283. doi: 10.1093/jat/bkx110.

PMID:
29300899
19.

Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts.

Petrous J, Furmaga K.

BMJ Case Rep. 2017 Oct 23;2017. pii: bcr-2017-222037. doi: 10.1136/bcr-2017-222037.

PMID:
29066641
20.

Benefits associated with switching from benzodiazepine hypnotics to suvorexant in patients with mild primary insomnia.

Suzuki H, Hibino H, Inoue Y, Mikami A, Matsumoto H, Mikami K.

Asian J Psychiatr. 2017 Oct;29:71-72. doi: 10.1016/j.ajp.2017.04.010. Epub 2017 Apr 22. No abstract available.

PMID:
29061431

Supplemental Content

Loading ...
Support Center